Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2598-2603

  Van Zuylen, Lia ^a   Verweij, Jaap ^a   Nooter, Kees ^a   Brouwer, Eric ^a   Stoter, Gerrit ^a   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GLYCOPROTEIN P; LANIQUIDAR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DETOXIFICATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FECES; HALF-LIFE; HUMANS; INTESTINAL MUCOSA; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; QUINOLINES; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0033927213     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bradshaw, D. M., and Arceci, R. J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol., 16: 3674-3690, 1998.
2. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
3. Twentyman, P. R. Transport proteins in drug resistance: biology and approaches to circumvention. J. Int. Med., 740: 133-137, 1997.
4. Randolph, G. J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L., Steinman, R. M., and Muller, W. A. A physiologic function for P-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. USA, 95: 6924-6929, 1998.
5. Van Asperen, J., Mayer, U., Van Tellingen, O., and Beijnen, J. H. The pharmacological role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci., 86: 881-884, 1997.
6. Verrelle, P., Meissonnier, F., Fonck, Y., Feillel, V., Dionet, C., Kwiatkowski, F., Plagne, R., and Chassagne, J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst., 83: 111-116, 1991.
7. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222, 1993.
8. Relling, M. V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monit., 18: 350-356, 1996.
9. Wacher, V. J., Wu, C-Y., and Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen., 13: 129-134, 1995.
10. Ringel, I., and Horwitz, S. B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl. Cancer Inst., 83: 288-291, 1991.
11. Walle, T., Walle, U. K., Kumar, G. N., and Bhalla, K. N. Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos., 23: 506-512, 1995.
12. Sparreboom, A., Van Tellingen, O., Scherenburg, E. J., Boesen, J. J. B., Huizing, M. T., Nooijen, W. J., Versluis, C., and Beijnen, J. H. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab. Dispos., 24: 655-661, 1996.
13. Loos, W. J., Verweij, J., Nooter, K., Stoter, G., and Sparreboom, A. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J. Chromatogr. B., 693: 437-441, 1997.
14. 14 radiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients. Proc. Am. Assoc. Cancer Res., 34: 373, 1993.
15. Monegier, B., Gaillard, C., Sable, S., and Vuilhorgne, M. Structures of the major human metabolites of docetaxel (RP 56976-Taxotere®). Tetrahedron Lett., 35: 3715-3718, 1994.
16. Rosing, H., Lustig, V., Koopman, F. J., Ten Bokkel Huinink, W. W., and Beijnen, J. H. Bioanalysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J. Chromatogr. B., 696: 89-98, 1997.
17. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestines. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
18. Van Asperen, J., Van Tellingen, O., and Beijnen, J. H. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol. Res., 37: 429-435, 1998.
19. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Preclinical pharmacokinetics of paclitaxel and docetaxel: a review. Anticancer Drugs, 9: 1-16, 1998.
20. Van Asperen, J., Van Tellingen, O., Van der Valk, M. A., Rozenhart, M., and Beijnen, J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res., 4: 2293-2297, 1998.
21. Meerum Terwogt, J. M., Beijnen, J. H., Ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet, 352: 285, 1998.